Dilated Cardiomyopathy

Meet the patient

A 29-year-old man walks into clinic with three months of breathlessness on the stairs, two pillows at night, and a 5 kg weight loss. His father died suddenly at 44 — "a heart attack, they said". The echo shows a globally dilated, thin-walled left ventricle with an ejection fraction of 30 percent and functional mitral regurgitation. The coronary angiogram is clean.[1][2]

Two exam questions are now live and you must answer both at consultant depth: why is this ventricle failing? (the aetiology hunt decides whether the disease is reversible) and what will keep him alive? (the four pillars, the ICD conversation, and the family he has not yet screened). Hold those two questions and the rest of the page slots into place.[1][3]

The 117-45 rule — the named number that makes the diagnosis

Dilated cardiomyopathy is defined by two numbers and one exclusion. The 2016 ESC revised definition (Pinto) made the diagnosis objective so that "it looks dilated to me" would no longer pass: the LV must be dilated AND systolic, AND the picture must not be explained by loading or by coronary disease.[2]

The two numbers every candidate must reproduce verbatim:[2]

• LV end-diastolic dimension (LVEDD), corrected for body surface area and sex, greater than 117 percent of the predicted value — equivalent to a Z-score over 2.
• LV ejection fraction under 45 percent (or fractional shortening under 25 percent).[1][2]

The one exclusion that does the heavy lifting: the systolic dysfunction must be unexplained by abnormal loading conditions (hypertension, valve disease, congenital heart disease) or by coronary artery disease sufficient to cause global systolic impairment. A dilated, failing ventricle with two-vessel CAD and a prior anterior Q-wave MI is ischaemic cardiomyopathy, not DCM — and the management fork is different.[1][2]

The number rule — call it 117-45. Say it as one breath in the viva: one-seventeen, forty-five, not loading, not ischaemic. That is the definition, and the rest of the page exists to defend those four words.[2]

Etymology for viva gold: cardiomyopathy, Greek kardia (heart) plus mys (muscle) plus pathos (suffering) — literally "disease of the heart muscle". The name survived because it excludes the three things the failing heart is NOT failing from: blocked arteries, leaking valves, or high pressure. Once those are gone, what remains is the muscle itself.[1]

Read the scar like the consultant does — the CMR LGE face-off

Cardiac MRI is the single highest-yield test in dilated cardiomyopathy, and the late-gadolinium-enhancement pattern is the discriminator examiners probe. Echo confirms the dilatation and the EF; CMR tells you why and who will die suddenly.[5]

The LGE pattern localises the disease in one image:[5]

[5]

The discriminator line: mid-wall = DCM; subepicardial inferolateral = myocarditis or sarcoid; subendocardial coronary = ischaemia (leave the DCM pathway); no scar = best prognosis. One sentence, and you have the highest-yield marks on the page.[5]

Why the ventricle dilates — five mechanisms, one final common pathway

DCM is not one disease — it is a final common pathway that many insults converge on. Genetic mutations, toxins, inflammation, tachycardia and metabolic derangement all end at the same five cellular events.[1][3]

1. Cardiomyocyte loss and impaired contractility. In genetic DCM, mutations in sarcomeric (TTN, MYH7, TPM1, TNNT2), Z-disc and cytoskeletal (DES, BAG3), nuclear-envelope (LMNA, EMD) and ion-channel or desmosomal (FLNC, PLN, SCN5A) proteins build a contractile apparatus that cannot withstand the cyclical load. Titin-truncating variants are the single commonest — the giant titin filament spans the sarcomere, and a truncation disrupts passive-tension sensing until the myocyte dies and is replaced by scar. In anthracycline injury, free-radical and topoisomerase damage does the same killing.[1]

2. Adverse remodelling. Loss of myocardium raises wall stress — Laplace: stress is proportional to (pressure times radius) divided by (twice wall thickness). Surviving myocytes slip past one another, the ventricle thins and dilates, and the mitral and tricuspid annuli stretch open into functional regurgitation. More volume returns, the chamber dilates further — a vicious cycle.[1]

3. Neurohormonal activation. The falling cardiac output is read as underperfusion: the sympathetic system fires catecholamines (chronically cardiotoxic — apoptosis, arrhythmia, hypokalaemia), the RAAS activates (angiotensin II vasoconstricts and drives fibrosis; aldosterone retains sodium and fibroses), and vasopressin rises (dilutional hyponatraemia). Each is initially compensatory, each is chronically toxic — and each is the target of one pillar of therapy.[3]

4. Fibrosis and arrhythmogenesis. Replacement fibrosis — visible as late gadolinium enhancement — replaces lost myocytes with non-conducting scar. Conduction slows, re-entry circuits form, and the substrate for ventricular arrhythmia and sudden death is born. Mid-wall septal LGE is the strongest CMR predictor of SCD in DCM (Gulati, JAMA 2013).[5]

5. Stasis and thromboembolism. The dilated, poorly contracting apex becomes a low-flow chamber. Combine that with atrial fibrillation from atrial stretch and endothelial dysfunction, and the patient generates apical mural thrombus and systemic emboli — the rationale for anticoagulation when EF is low, AF is present, or a thrombus is seen.[1]

Always find the treatable cause before you say idiopathic

The most useful sentence in DCM is "the cause is treatable". Alcohol, tachycardia, thyroid disease, iron deficiency, sarcoidosis, the peripartum state and anthracycline exposure are all reversible or arrestable — and "idiopathic DCM" is usually a diagnosis you made before you finished the work-up.[1]

Aetiology is the clinically useful axis because it decides reversibility. The familial proportion is 30 to 50 percent (autosomal-dominant in the great majority), and titin-truncating variants are the single largest gene, found in roughly 15 to 25 percent of familial and 8 to 18 percent of sporadic DCM. A three-generation pedigree — capturing every sudden death under 50, every pacemaker or ICD, every transplant, every unexplained heart failure — is the cheapest, highest-yield piece of the work-up.[1]

[1] [1] [6]

The DILATED mnemonic — carry it onto the ward round and you will not miss a reversible cause:[1]

[1] [1]

The classic trap — the dilated LV that is actually ischaemic

Before you write DCM, you must exclude the mimics — and ischaemic cardiomyopathy is by far the commonest. Roughly two-thirds of all dilated, poorly contracting left ventricles come from coronary disease, and the management fork (revascularisation versus genetic testing and family screening) hangs on getting this right.[1][2]

[1] [5]

The discriminator line: subendocardial LGE in a coronary territory is ischaemia — leave the DCM pathway and go to the cath lab. Everything else is a clinical-plus-imaging judgement, but that one is categorical.[1]

The classic trap: a young person with a dilated LV and normal coronaries is not necessarily "idiopathic" — the commonest missed causes are a silent recent viral myocarditis (CMR shows subepicardial inferolateral LGE and T2 oedema), an unrecognised tachycardiomyopathy (check the Holter for a 15 percent PVC burden), and a family history nobody took. Idiopathic is a label of exclusion, never a working diagnosis.[1][6]

The four pillars together, then the device — the management spine

[1]

DCM management has four layers: treat the cause, the four pillars of HFrEF, device therapy, and advanced therapies — in that order. The cause work-up runs in parallel with the first prescription; the device decision waits at least three months for the GDMT to work.[1][3]

Layer 1 — Treat the cause

Reversible DCMs recover dramatically once the trigger is removed. Name the intervention alongside the cause, because that is how it is examined:[1]

• Alcohol abstinence — up to one-third of alcoholic DCMs recover substantial EF; refer to alcohol-liaison services.
• Tachycardia-induced — rate or rhythm control (beta-blocker, ablation for a focal atrial tachycardia or high-burden PVCs); EF recovers within 1 to 6 months.
• Thyroid disease — levothyroxine for hypothyroidism; carbimazole for thyrotoxicosis; both can produce dramatic recovery.
• Iron deficiency — IV ferric carboxymaltose improves symptoms and exercise capacity in HFrEF irrespective of anaemia.
• Haemochromatosis — therapeutic phlebotomy (target ferritin under 100) or chelation; halts progression if caught early.
• Sarcoidosis — corticosteroids (prednisolone 0.5 to 1 mg per kg per day tapering) for biopsy-proven or FDG-PET-positive cardiac sarcoid.
• Autoimmune myocarditis (virus-negative, biopsy-proven) — immunosuppression; giant-cell myocarditis demands urgent combination immunosuppression and transplant evaluation.
• Peripartum cardiomyopathy — pregnancy-compatible GDMT plus bromocriptine 2.5 mg twice daily for 8 weeks (see the named subtypes below).[1][8][9]

Layer 2 — The four pillars of HFrEF, started together

Each pillar carries an independent mortality benefit. Start all four together at low dose and titrate to target — do not sequence them, and do not wait for "the patient to settle" first.[3][4]

[1] [3] [4] [10]

Named evidence for the consultant viva — carvedilol in non-ischaemic DCM. The US Carvedilol Heart Failure Study (Packer, Circulation 1996) showed carvedilol cut mortality by roughly two-thirds in chronic HFrEF, with particular benefit in the non-ischaemic DCM subgroup. That is why carvedilol is the beta-blocker examiners reach for first in a young patient with idiopathic DCM.[10]

Adjuncts that do not change mortality but change symptoms:[1]

• Loop diuretic — furosemide 20 to 80 mg orally daily for congestion; symptom control only, no mortality benefit. Add metolazone 2.5 to 5 mg for resistance (sequential nephron blockade, watch electrolytes).
• Ivabradine — sinus rhythm with heart rate 70 or more despite maximally tolerated beta-blocker; inhibits the SA-node If current; no benefit in AF.
• Hydralazine-nitrate — African ancestry, or ACEi/ARNI intolerance; hydralazine 37.5 mg plus isosorbide dinitrate 20 mg three times daily.
• Digoxin — symptom or rate control in AF; narrow window 0.5 to 0.9 ng per mL; no mortality benefit; avoid in renal failure and conduction disease.[1]

Layer 3 — Device therapy, and the DANISH trap

The device decision waits at least three months for the GDMT to do its work — because EF recovers, especially in non-ischaemic DCM, and a device you implanted in month one may be unnecessary by month four.[3][4]

ICD for primary prevention of sudden cardiac death is indicated for EF under 35 percent, NYHA II to III, expected survival over one year, after at least three months of optimal medical therapy.[3][4]

Cardiac resynchronisation therapy (CRT) is indicated for QRS over 150 ms with LBBB morphology and EF under 35 percent in sinus rhythm (Class I); benefit is less certain for QRS 120 to 149 ms or non-LBBB. Prefer CRT-D (with defibrillator) in DCM unless contraindicated.[3][4]

The high-arrhythmia genotypes — a named trap. In LMNA, FLNC, PLN, and RBM20 mutation carriers, malignant ventricular arrhythmia can precede contractile failure — so the standard EF-under-35 threshold will miss them. An ICD may be indicated at higher EF in these genotypes, particularly with conduction disease (LMNA), non-sustained VT, or a family history of sudden death. This is the one group in which genetics change the device threshold.[1]

Layer 4 — Anticoagulation

Anticoagulate for atrial fibrillation (by CHA2DS2-VASc), LV apical thrombus, or prior thromboembolism. A DOAC (apixaban 5 mg twice daily, rivaroxaban 20 mg daily, dabigatran 150 mg twice daily) is preferred over warfarin in non-valvular AF; warfarin (INR 2 to 3) remains standard for LV thrombus, where DOAC evidence is limited. Severe LV dysfunction with EF under 30 percent is debated — weigh individual risk.[1]

Layer 5 — Advanced therapies

Cardiac transplantation is the gold standard for end-stage DCM refractory to optimal therapy — indications include peak VO2 under 12 to 14 mL per kg per min, recurrent hospitalisation, refractory ventricular arrhythmia, and cardiogenic shock needing inotropes or mechanical support. A durable LVAD (HeartMate 3) is a bridge to transplant or destination therapy. And do not forget palliative care for the patient who is not a transplant candidate — symptom focus, and deactivate ICD shocks at end of life.[1]

[1] [2]

The named subtypes that earn viva marks

Two subtypes come up again and again because each carries a mechanism, a treatment, and a recovery rate that examiners love. Peripartum cardiomyopathy and cancer-therapy-related cardiomyopathy are not footnotes — they are stems.[1][8]

Peripartum cardiomyopathy — the 16-kDa prolactin fragment

PPCM is heart failure with EF under 45 percent in the last month of pregnancy or the first five months postpartum, with no other cause. The mechanism is a peripartum oxidative-stress cleavage of prolactin into a 16-kDa anti-angiogenic fragment that destroys the cardiac microvasculature — and that mechanism is the rationale for bromocriptine.[8]

PPCM shares its genetics with DCM: titin-truncating variants are found in 6 to 15 percent of PPCM, the same largest gene as familial DCM. A first-degree-relative history of DCM or sudden death should raise the index of suspicion in any breathless peripartum woman.[8]

Management is standard GDMT modified for pregnancy, plus bromocriptine:[8][9]

• Avoid ACEi, ARB, and MRA in pregnancy — teratogenic. Use hydralazine-nitrate for afterload reduction instead.
• Beta-blocker: metoprolol or bisoprolol (avoid atenolol — intrauterine growth restriction).
• Start ACEi, ARB, and MRA postpartum if not breastfeeding.
• Bromocriptine 2.5 mg twice daily for 8 weeks — suppresses the 16-kDa prolactin fragment; stop breastfeeding.
• Anticoagulate if EF under 30 percent (high thrombus risk in the puerperium).[8]

Recovery is the headline. With contemporary guideline therapy, 50 to 70 percent of PPCM patients recover EF to above 50 percent (Moulig, 2019) — far better than most DCM. But recurrence in a subsequent pregnancy is high, so counsel accordingly.[9]

Anthracycline versus trastuzumab — the Type 1 / Type 2 face-off

Cancer-therapy-related cardiomyopathy comes in two flavours, and the distinction is examined because the prognosis is opposite:[1]

[1] [1]

The discriminator line: dose-dependent and irreversible = anthracycline (Type 1); not dose-dependent and reversible = trastuzumab (Type 2). Surveillance is the same for both — baseline echo and troponin, repeat at 3, 6, 9, 12 months for high-risk regimens, with global longitudinal strain as the earliest flag before EF falls. Dexrazoxane (iron chelator) before high-dose anthracycline is the one preventive therapy that works.[1]

Screen the family — the single most under-applied life-saving intervention

If you do one thing after diagnosing DCM, screen the first-degree relatives. Familial disease is 30 to 50 percent of DCM, and a pathogenic variant is often found in a relative whose EF is still normal but whose ventricle is already dilating silently.[1]

The standard is clinical screening — ECG, echo, and consider CMR — of all first-degree relatives, every 1 to 3 years, starting at age 10. If a pathogenic variant is identified in the proband, offer targeted cascade genetic testing to relatives: a carrier enters surveillance, a non-carrier is discharged. This is cheap, it is effective, and it is the intervention most consistently missed in routine practice.[1]

Genetic testing with a targeted next-generation sequencing panel is recommended in any DCM with a family history, conduction disease (think LMNA), sudden death in the family, or onset under 50. A pathogenic or likely-pathogenic variant is found in roughly 25 to 40 percent of familial DCM and 10 to 20 percent of apparently sporadic DCM — and each finding triggers cascade testing.[1]

Ward-round test — three stems

Stem 1 — the young man with a new failing ventricle and clean coronaries

A 29-year-old man presents with three months of progressive dyspnoea, two-pillow orthopnoea, and a family history of sudden death under 50. Echo shows a dilated thin-walled LV with EF 30 percent and functional MR; coronary angiography is normal. What is the aetiological work-up, and what is the first prescription? Model: This is non-ischaemic dilated cardiomyopathy by the 117-45 rule. The work-up is cardiac MRI (LGE pattern — mid-wall septal points to DCM, subepicardial inferolateral to myocarditis), a three-generation pedigree and targeted genetic panel (titin, LMNA, FLNC, PLN, RBM20), Holter for non-sustained VT and PVC burden, and a biochemical hunt for a reversible cause — alcohol history, thyroid function, iron studies, viral serology, ANA, and serum ACE. Start the four pillars together at low dose — ARNI (or ACEi after a 36-hour washout), carvedilol, MRA, SGLT2i — once euvolaemic, and titrate to target. Counsel on alcohol abstinence, and screen the first-degree relatives.[1][2]

Stem 2 — the peripartum woman with EF 25 percent

A 31-year-old woman presents three weeks after an uneventful delivery with dyspnoea, orthopnoea, and bibasal crackles. Echo shows EF 25 percent with a dilated LV. She is breastfeeding and wants to continue. What changes about her heart-failure therapy? Model: This is peripartum cardiomyopathy — EF under 45 percent in the first five months postpartum with no other cause, driven by a 16-kDa prolactin fragment. Modify the GDMT for the puerperium: avoid ACEi, ARB, and MRA if she continues breastfeeding (and they were contraindicated in pregnancy anyway), use hydralazine-nitrate for afterload reduction and a beta-blocker (metoprolol or bisoprolol), add a loop diuretic for congestion, anticoagulate because EF is under 30 percent, and start bromocriptine 2.5 mg twice daily for 8 weeks — which means she must stop breastfeeding. Counsel that 50 to 70 percent recover EF, and that a subsequent pregnancy carries a high recurrence risk.[8][9]

Stem 3 — non-ischaemic DCM, EF 32 percent after four months of optimal therapy, age 72

A 72-year-old man with non-ischaemic DCM has been on target-dose ARNI, beta-blocker, MRA, and SGLT2i for four months. His EF has risen from 28 to 32 percent. He is NYHA II. The registrar books him for ICD implantation. What is the right conversation? Model: The DANISH trial (2016) showed ICD did not reduce all-cause mortality in non-ischaemic systolic heart failure, and the benefit was smallest in patients over 70. He technically meets the EF-under-35 threshold after three months of optimal therapy, but this is now a shared decision-making conversation, not an automatic implant. Lay out the small absolute mortality benefit, the risks (infection, inappropriate shock, lead failure), his competing non-arrhythmic risks, and the option of a wearable cardioverter-defibrillator or continued medical therapy. Check a CMR for mid-wall LGE and a genetic panel — high-arrhythmia genotypes (LMNA, FLNC, PLN, RBM20) shift the balance toward ICD even at this age. The patient decides with you, not the guideline alone.[7][5]

The mantra

Dilated thin ventricle, find the cause, four pillars together, mid-wall scar predicts sudden death, screen the family.[1][3]

References

1. [1]Bozkurt B, Colvin M, Cook J, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association Circulation, 2016.PMID 27832612
2. [2]Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases Eur Heart J, 2016.PMID 26792875
3. [3]McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J, 2023.PMID 37622666
4. [4]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines J Am Coll Cardiol, 2022.PMID 35379504
5. [5]Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy JAMA, 2013.PMID 23462786
6. [6]Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J, 2013.PMID 23824828
7. [7]Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure N Engl J Med, 2016.PMID 27571011
8. [8]Ware JS, Li J, Mazaika E, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies N Engl J Med, 2016.PMID 26735901
9. [9]Moulig V, Pfeffer TJ, Ricke-Hoch M, et al. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities Eur J Heart Fail, 2019.PMID 31724271
10. [10]Packer M, Bristow MR, Cohn JN, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group Circulation, 1996.PMID 8941105